Article Text

Download PDFPDF
SuPAR, an emerging biomarker in kidney and inflammatory diseases
  1. Lamiaa Hamie1,
  2. Georges Daoud1,
  3. Georges Nemer2,
  4. Tarek Nammour3,
  5. Alissar El Chediak3,
  6. Imad W Uthman3,
  7. Abdul Ghani Kibbi4,
  8. Assaad Eid1,
  9. Mazen Kurban2,4
  1. 1 Department of Anatomy, Cell Biology and Physiological Sciences, Faculty of Medicine, American University of Beirut, Beirut, Lebanon
  2. 2 Department of Biochemistry and Molecular Genetics, Faculty of Medicine, American University of Beirut, Beirut, Lebanon
  3. 3 Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon
  4. 4 Department of Dermatology, American University of Beirut Medical Center, Beirut, Lebanon
  1. Correspondence to Dr Mazen Kurban, Department of Dermatology Biochemistry and Molecular Genetics, American University of Beirut Medical Center, Beirut, Lebanon; mk104{at}


Soluble urokinase plasminogen activator receptor (suPAR) is a circulating form of a physiological and pathophysiological important cell surface receptor, implicated in inflammation. Recent studies showed that suPAR is a promising biomarker, useful for diagnosis, assessment and prognosis of several diseases. This review summarises the majority of preliminary studies and analyses the significance and the clinical application of suPAR in various clinical conditions. SuPAR seems to have a significant value in the diagnosis as well as prognosis of many diseases; nonetheless, it merits large-scale studies to set cut-off values that help physicians in following up their patients and accordingly tailor their treatment plans.

  • biomarker
  • diagnosis
  • inflammation
  • prognosis
  • screen
  • soluble urokinase plasminogen activator receptor
View Full Text

Statistics from


  • LH and GD contributed equally.

  • Contributors LH and MK planned the study. LH, GD, TN and AEC contributed to the writing of the manuscript. IWU, AGK, AE, MK and GN were responsible for reviewing the manuscript. LH and TN created the figures and tables. LH submitted the manuscript.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient consent Not required.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.